



# Human Anti-Human PD-L1 (Atezolizumab) Monoclonal Antibody, clone Atezolizumab [Biosimilar] (CABT-Z660H)

This product is for research use only and is not intended for diagnostic use.

## PRODUCT INFORMATION

<b>Product Overview</b>	Biosimilar Recombinant Human Monoclonal Antibody
<b>Immunogen</b>	Human PD-L1
<b>Isotype</b>	IgG1
<b>Source/Host</b>	Human
<b>Species Reactivity</b>	Human
<b>Clone</b>	Atezolizumab
<b>Purification</b>	Protein A purified
<b>Conjugate</b>	Functional Grade
<b>Applications</b>	FC, WB
<b>Format</b>	Liquid
<b>Concentration</b>	Lot specific
<b>Size</b>	1 mg
<b>Buffer</b>	PBS, pH 7.0. Endotoxin Level $\leq$ 1.0 EU/mg as determined by the LAL method.
<b>Preservative</b>	None
<b>Storage</b>	The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.

---

Ship

Wet ice

---

## BACKGROUND

### Introduction

PD-L1 (programmed death ligand 1) also known as B7-H1 or CD274. PD-L1 is a 40 kDa type I transmembrane protein that belongs to the B7 family of the Ig superfamily. PD-L1 is expressed on T lymphocytes, B lymphocytes, NK cells, dendritic cells, as well as IFNy stimulated monocytes, epithelial cells and endothelial cells. PD-L1 binds to its receptor, PD-1, found on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. Engagement of PD-L1 with PD-1 leads to inhibition of TCR-mediated T cell proliferation and cytokine production. PD-L1 is thought to play an important role in tumor immune evasion. Induced PD-L1 expression is common in many tumors and results in increased resistance of tumor cells to CD8 T cell mediated lysis.

---

### Keywords

CD274;CD274 molecule;B7-H;PDL1;PD-L1

---

## GENE INFORMATION

Gene Name CD274

---

Entrez Gene ID [29126](#)

---

UniProt ID [Q9NZQ7](#)

---